**Core Concept**
The underlying principle being tested here is the management of contralateral breast cancer risk in patients diagnosed with breast carcinoma. This involves assessing the risk of developing breast cancer in the unaffected breast and taking appropriate preventive measures.

**Why the Correct Answer is Right**
The correct answer involves considering the patient's risk factors, such as family history, genetic mutations (e.g., BRCA1 and BRCA2), and personal history of breast cancer. In patients with a high risk of developing breast cancer, preventive measures such as **contralateral prophylactic mastectomy (CPM)** or **chemoprevention** with medications like tamoxifen or raloxifene may be recommended. CPM involves surgically removing both breasts to eliminate the risk of breast cancer in the unaffected breast.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not address the risk of developing breast cancer in the unaffected breast.
* **Option B:** This option is incorrect because it does not provide a clear preventive measure for contralateral breast cancer risk.
* **Option C:** This option is incorrect because it is not a commonly recommended preventive measure for contralateral breast cancer risk.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that the decision to perform CPM or chemoprevention should be individualized and based on the patient's specific risk factors and preferences. The National Comprehensive Cancer Network (NCCN) guidelines provide a framework for assessing and managing contralateral breast cancer risk.

**Correct Answer: C. Contralateral Prophylactic Mastectomy (CPM)**